Original
Diez años de experiencia con el primer biosimilar autorizado de hormona del crecimiento recombinante humana en la práctica clínica habitual
Ten years experience with the first approved biosimilar recombinant human growth hormone drug in normal clinical practice
Juan Pedro López-Sigueroa, Margarida Palla Garcíab, Elena Martínez Bustob,
, Francisco José Rebollob, Manuel Pomboc
a Endocrinología Pediátrica, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España
b Sandoz Farmacéutica SA, Centro Empresarial Parque Norte, Madrid, España
c Facultad de Medicina, Universidad Santiago de Compostela, Santiago de Compostela, A Coruña, España
Leído
11725
Vecesse ha leído el artículo
2977
Total PDF
8748
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 146 | 26 | 172 |
| 2025 5 | 201 | 40 | 241 |
| 2025 4 | 188 | 30 | 218 |
| 2025 3 | 168 | 16 | 184 |
| 2025 2 | 165 | 29 | 194 |
| 2025 1 | 111 | 26 | 137 |
| 2024 12 | 126 | 37 | 163 |
| 2024 11 | 149 | 60 | 209 |
| 2024 10 | 152 | 38 | 190 |
| 2024 9 | 138 | 29 | 167 |
| 2024 8 | 132 | 61 | 193 |
| 2024 7 | 118 | 30 | 148 |
| 2024 6 | 128 | 27 | 155 |
| 2024 5 | 152 | 39 | 191 |
| 2024 4 | 156 | 32 | 188 |
| 2024 3 | 102 | 28 | 130 |
| 2024 2 | 109 | 36 | 145 |
| 2024 1 | 127 | 22 | 149 |
| 2023 12 | 103 | 12 | 115 |
| 2023 11 | 116 | 19 | 135 |
| 2023 10 | 119 | 24 | 143 |
| 2023 9 | 110 | 31 | 141 |
| 2023 8 | 109 | 15 | 124 |
| 2023 7 | 96 | 32 | 128 |
| 2023 6 | 101 | 24 | 125 |
| 2023 5 | 111 | 30 | 141 |
| 2023 4 | 70 | 21 | 91 |
| 2023 3 | 125 | 27 | 152 |
| 2023 2 | 140 | 28 | 168 |
| 2022 1 | 114 | 18 | 132 |
| 2022 12 | 117 | 22 | 139 |
| 2022 11 | 117 | 34 | 151 |
| 2022 10 | 127 | 57 | 184 |
| 2022 9 | 82 | 39 | 121 |
| 2022 8 | 66 | 57 | 123 |
| 2022 7 | 76 | 38 | 114 |
| 2022 6 | 51 | 46 | 97 |
| 2022 5 | 65 | 40 | 105 |
| 2022 4 | 72 | 36 | 108 |
| 2022 3 | 91 | 51 | 142 |
| 2022 2 | 84 | 29 | 113 |
| 2021 1 | 91 | 34 | 125 |
| 2021 12 | 104 | 44 | 148 |
| 2021 11 | 101 | 41 | 142 |
| 2021 10 | 110 | 83 | 193 |
| 2021 9 | 92 | 46 | 138 |
| 2021 8 | 99 | 45 | 144 |
| 2021 7 | 67 | 35 | 102 |
| 2021 6 | 86 | 60 | 146 |
| 2021 5 | 88 | 39 | 127 |
| 2021 4 | 171 | 115 | 286 |
| 2021 3 | 132 | 48 | 180 |
| 2021 2 | 94 | 24 | 118 |
| 2020 1 | 95 | 32 | 127 |
| 2020 12 | 99 | 32 | 131 |
| 2020 11 | 81 | 26 | 107 |
| 2020 10 | 83 | 12 | 95 |
| 2020 9 | 43 | 17 | 60 |
| 2020 8 | 62 | 8 | 70 |
| 2020 7 | 77 | 28 | 105 |
| 2020 6 | 63 | 12 | 75 |
| 2020 5 | 57 | 24 | 81 |
| 2020 4 | 62 | 27 | 89 |
| 2020 3 | 75 | 30 | 105 |
| 2020 2 | 68 | 20 | 88 |
| 2020 1 | 68 | 25 | 93 |
| 2019 12 | 89 | 29 | 118 |
| 2019 11 | 58 | 18 | 76 |
| 2019 10 | 63 | 19 | 82 |
| 2019 9 | 65 | 20 | 85 |
| 2019 8 | 72 | 37 | 109 |
| 2019 7 | 54 | 26 | 80 |
| 2019 6 | 54 | 22 | 76 |
| 2019 5 | 223 | 31 | 254 |
| 2019 4 | 178 | 47 | 225 |
| 2019 3 | 106 | 40 | 146 |
| 2019 2 | 78 | 22 | 100 |
| 2019 1 | 92 | 49 | 141 |
| 2018 12 | 102 | 57 | 159 |
| 2018 11 | 138 | 57 | 195 |
| 2018 10 | 184 | 46 | 230 |
| 2018 9 | 128 | 28 | 156 |
| 2018 8 | 3 | 0 | 3 |
| 2018 7 | 11 | 0 | 11 |
| 2018 6 | 13 | 0 | 13 |
| 2018 5 | 22 | 0 | 22 |
| 2018 4 | 17 | 9 | 26 |
| 2018 3 | 0 | 17 | 17 |
| 2018 2 | 0 | 10 | 10 |
| 2018 1 | 0 | 20 | 20 |
| 2017 12 | 0 | 18 | 18 |
| 2017 11 | 0 | 20 | 20 |
| 2017 10 | 0 | 24 | 24 |
| 2017 9 | 0 | 24 | 24 |
| 2017 8 | 0 | 24 | 24 |
| 2017 7 | 0 | 18 | 18 |
| 2017 6 | 0 | 2 | 2 |
Mostrar todo
